Jefferies rates Australia's 4DMedical 'buy' on FDA approval

4DMedical

28/09/2025 22:08

** Analysts at Jefferies set PT of Australia's 4DMedical 4DX.AX at A$2.5; initiate with a "buy" rating

** Jefferies says the medical technology firm's FDA approval and U.S. Centers for Medicare & Medicaid Services reimbursement for CT:VQ software solution unlocked critical inflection point to see 4DX succeed

** For 4DMedical to be cash-flow positive by FY28, CT:VQ needs to be adopted by 11% of the total potential U.S. market; expects 14% penetration by that period - Jefferies

** Adds 4DX's X-ray Velocimetry Lung Ventilation Analysis Software could provide a further growth trigger

** Investment bank forecasts EBITDA losses of A$32.6 million ($21.34 million) and A$6.8 million in FY26 and FY27, respectively; expects EBITDA turnaround to A$9.2 million in FY28

** 4DX, YTD up 277.1%, as of last close

($1 = 1.5279 Australian dollars)

 (Reporting by Keshav Singh Chundawat in Bengaluru)

 ((Keshav.singhchundawat@thomsonreuters.com))